Tuesday, March 28, 2023
Psoriasis Resource Center
Patients with moderate-to-severe psoriasis experience a high burden of disease, including physical factors, such as itching and pain; and psychosocial factors, such as embarrassment, anxiety, or depression. They experience frustration with chronic treatments that may or may not work, and quality of life (QoL) issues. Collaborative patient-clinician communication and shared-decision making are crucial to identify appropriate treatment strategies. Implementing individualized treat-to-target strategies with patient goal-setting can help reduce disease burden and improve QoL.
Developed through a partnership between Medscape and the National Psoriasis Foundation (NPF)
Supported by an education grant from
Lilly
Steering Committee Chair
Waldman Professor and Chairman
Kimberly and Eric J. Waldman Department of Dermatology
Icahn School of Medicine at Mount Sinai
New York, New York
Nurse Practitioner
VA Portland Health Care System
Portland, Oregon
James E. Elder, MD, Endowed Professor for Graduate Education
Chair
Residency Program Director
Department of Dermatology
University of Alabama at Birmingham
Birmingham, Alabama
Chair and Professor of Dermatology
Medical College of Wisconsin
Milwaukee, Wisconsin
Assistant Professor
System Medical Director
Department of Dermatology
Mount Sinai Healthcare System
Chief of Teledermatology
Department of Dermatology
Icahn School of Medicine at Mount Sinai
New York, New York
Professor and Chair
Department of Dermatology
Eastern Virginia Medical School
Norfolk, Virginia
Steering Committee Chair
Has disclosed the following relevant financial relationships
Received grants for clinical research from: AbbVie; Amgen; Arcutis; AstraZeneca; Boehringer Ingelheim; Celgene; Clinuvel; Incyte; Janssen Research & Development, LLC; Kadmon Corp., LLC; Leo Pharmaceuticals; Lilly; MedImmune; Novartis; Ortho Dermatologics; Pfizer; Sciderm; UCB, Inc.; ViDac
Has disclosed the following relevant financial relationships
Served as an advisor or consultant for: AbbVie; Celgene; Lilly; Regeneron; Sanofi Genzyme; Sun Pharma
Served as a speaker or a member of a speakers bureau for: AbbVie; Lilly; Regeneron; Sanofi Genzyme; Sun Pharma
Has disclosed the following relevant financial relationships
Served as an advisor or consultant for: Boehringer Ingelheim; Bristol Myers Squibb; Celgene; Leo Pharmaceuticals; Lilly; Menlo; Novartis; Pfizer; Sun Pharma; Valeant (Ortho dermatology); Verrica
Received grants for clinical research from: AbbVie; Anaptys Bio; Boehringer Ingelheim; Bristol Myers Squibb; Celgene; Incyte; Leo Pharmaceuticals; Lilly; Menlo; Merck; Novartis; Pfizer; Regeneron; Sun Pharma; Valeant (Ortho dermatology); Vanda
Has disclosed the following relevant financial relationships
Served as an advisor or consultant for: AbbVie; Almiral; Amgen; Bristol Myers Squibb; Celgene; Dermavant; Dermira; Janssen; Leo Pharmaceuticals; Lilly; Novartis; Ortho Dermatologics; Pfizer; Sun Pharma; UCB, Inc.
Received grants for clinical research from: AbbVie; Bristol Myers Squibb; Celgene; Janssen; Lilly; Novartis; UCB, Inc.
Has disclosed the following relevant financial relationships
Served as an advisor or consultant for: Janssen; Leo Pharmaceuticals; Lilly; Ortho Dermatologics; Regeneron; Sanofi Genzyme; UCB, Inc.
Served as a speaker or a member of a speakers bureau for: AbbVie; Pfizer; Regeneron; Sanofi; Sun Pharma
Received grants for clinical research from: Bond Avillion; Celgene; Janssen; Lilly; Novartis; Pfizer; UCB, Inc.
Has disclosed the following relevant financial relationships
Served as an advisor or consultant for: Boehringer Ingelheim; Bristol Myers Squibb; Celgene; DermTech; Novartis; UCB, Inc.
Received grants for clinical research from: AbbVie; Celgene; Lilly